Precision Biosciences is a clinical-stage gene editing company developing in vivo therapies using its proprietary ARCUS meganuclease platform, which performs precise DNA cuts without requiring guide RNA and can enable gene insertion, elimination, and excision. The company advances wholly-owned programs targeting rare genetic and infectious diseases, including treatments for chronic hepatitis B (viral elimination), Duchenne muscular dystrophy (exon excision), and metabolic disorders, while generating revenue through milestone and royalty payments from partnered programs with companies such as iECURE, Caribou Biosciences, and others. Precision competes in the genome editing and gene therapy space by leveraging ARCUS's technological differentiation—compact size, single-component architecture, and precise cutting—to address unmet needs in hepatitis B, muscular dystrophy, and other rare diseases affecting millions globally.